Lack of effect of TP53 status on fluorodeoxyuridine-mediated radiosensitization

Radiation Research

Volumn 154, Issue 2, 2000, Pages 140-144

  Lawrence, Theodore S ^a   Burke, Renee ^a   Davis, Mary A ^a   Wygoda, Marc R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLOXURIDINE; PROTEIN P53;

CONFERENCE PAPER; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION;

EID: 0033857796     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/0033-7587(2000)154[0140:LOEOTS]2.0.CO;2     Document Type: Conference Paper

References (37)

1. C. J. McGinn, D. S. Shewach and T. S. Lawrence, Radiosensitizing nucleosides. J. Natl. Cancer Inst. 88, 1193-1203 (1996).
2. M. A. Davis, H. Y. Tang, J. Maybaum and T. S. Lawrence, Dependence of fluorodeoxyuridine-mediated radiosensitization on S phase progression. Int. J. Radiat. Biol. 67, 509-512 (1995).
3. C. E. Bruso, D. S. Shewach and T. S. Lawrence, Fluorodeoxyuridine-induced radiosensitization and inhibition of DNA double strand break repair in human colon cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 19, 1411-1417 (1990).
4. C. J. McGinn, E. M. Miller, M. J. Lindstrom, K. A. Kunugi, P. G. Johnston and T. J. Kinsella, The role of cell cycle redistribution in radiosensitization: Implications regarding the mechanism of fluorodeoxyuridine radiosensitization. Int. J. Radiat. Oncol. Biol. Phys. 30, 851-859 (1994).
5. T. S. Lawrence, M. A. Davis, H-Y. Tang and J. Maybaum, Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization require S phase progression. Int. J. Radiat. Biol. 70, 273-280 (1996).
6. T. S. Lawrence, M. A. Davis and T. L. Loney, Fluoropyrimidine-mediated radiosensitization depends on cyclin E-dependent kinase activation. Cancer Res. 56, 3203-3206 (1996).
7. S. W. Lowe, H. E. Ruley, T. Jacks and D. E. Housman, p53-dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell 74, 957-967 (1993).
8. D. Michalovitz, O. Halvey and M. Orens, Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62, 671-680 (1990).
9. J. D. Naida, M. A. Davis and T. S. Lawrence, The effect of activation of wild-type p53 function on fluoropyrimidine-mediated radiosensitization. Int. J. Radiat. Oncol. Biol. Phys. 41, 675-680 (1998).
10. 1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 10, 934-947 (1996).
11. S. Matsui, A. Arrendondo, C. Wrzosek and Y. M. Rustum, DNA damage and p53 induction do not cause ZD1694-induced cell cycle arrest in human colon carcinoma cells. Cancer Res. 56, 4715-4723 (1996).
12. 2 phase checkpoints. Cancer Surveys 29, 151-182 (1997).
13. S. E. Morgan and M. B. Kastan, p53 and ATM: Cell cycle, cell death, and cancer. Adv. Cancer Res. 71, 1-25 (1997).
14. C. J. Sherr, Cancer cell cycles. Science 274, 1672-1677 (1996).
15. D. Laird and D. Shalloway, Oncoprotein signaling and mitosis. Cell. Signalling 9, 249-255 (1997).
16. L. S. Cox and D. P. Lane, Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage. Bioessays 17, 501-508 (1995).
17. T. S. Lawrence, M. A. Davis, J. Maybaum, S. K. Mukhopadhay, P. L. Stetson, D. P. Normolle, P. E. McKeever and W. D. Ensminger, The potential superiority of bromodeoxyuridine to iododeoxyuridine as a radiation sensitizer in the treatment of colorectal cancer. Cancer Res. 52, 3698-3704 (1992).
18. M. L. Smith, I. T. Chen, Q. Zhan, P. M. O'Connor and A. J. Fornace, Jr., Involvement of the p53 tumor suppressor in repair of U.V.-type DNA damage. Oncogene 10, 1053-1059 (1995).
19. B. Fertil, H. Dertinger, A. Courdi and E. P. Malaise, Mean inactivation dose: A useful concept for intercomparison of human cell survival curves. Radiat. Res. 99, 73-84 (1984).
20. S. W. Lowe, S. Bodis, A. McClatchey, L. Remington, H. E. Ruley, D. E. Fisher, D. E. Housman and T. Jacks, P53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810 (1994).
21. R. Zellars, J. Naida, M. A. Davis and T. S. Lawrence, The effect of p53 overexpression on radiation sensitivity of human colon cancer cells. Radiat. Oncol. Invest. 5, 43-49 (1997).
22. G. Brachman, M. Beckett, D. Graves, D. Haraf, E. Yokes and R. Weichelsbaum, p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res. 53, 3667-3669 (1993).
23. M. Jung, V. Notario and A. Dritschilo, Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res. 52, 6390-6393 (1992).
24. 1 checkpoint does not decrease cell survival following DNA damage. Cancer Res. 53, 164-168 (1993).
25. S. Fan, M. L. Smith, D. J. Rivet, D. Duba, Q. Zhan, K. W. Kohn, A. J. Fornace and P. M. O'Connor, Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res. 55, 1649-1654 (1995).
26. S. Hawkins, G. W. Demers and D. A. Galloway, Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res. 56, 892-898 (1996).
27. B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein and R. W. Craig, Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311 (1991).
28. L. H. Hartwell and M. B. Kastan, Cell cycle control and cancer. Science 266, 1821-1828 (1994).
29. J. F. Boylan, D. M. Sharp, L. Leffett, A. Bowers and W. Pan, Analysis of site-specific phosphorylation of the retinoblastoma protein during cell cycle progression. Exp. Cell Res. 248, 110-114 (1999).
30. L. Connell-Crowley, J. W. Harper and D. W. Goodrich, Cyclin D1/ Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation. Mol. Biol. Cell 8, 287-301 (1997).
31. Y. Watanabe, T. Watanabe, M. Kitagawa, Y. Taya, K. Nakayama and N. Motoyama, pRb phosphorylation is regulated differentially by cyclin-dependent kinase (Cdk) 2 and Cdk4 in retinoic acid-induced neuronal differentiation of P19 cells. Brain Res. 842, 342-350 (1999).
32. D. W. Kufe, P. Scott, R. Fram and P. Major, Biologic effect of 5-fluoro-2′-deoxyuridine incorporation in L1210 deoxyribonucleic acid. Biochem. Pharmacol. 32, 1337-1340 (1983).
33. D. M. Pritchard, A. J. Watson, C. S. Potten, A. L. Jackman and J. A. Hickman, Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc. Natl. Acad. Sci. USA 94, 1795-1799 (1997).
34. M. D. Axelson, M. A. Davis, S. P. Ethier and T. S. Lawrence, HPV16-E7 Expression causes fluorodeoxyuridine-mediated radiosensitization in SW620 human colon cancer cells. Neoplasia 1, 177-182 (1999).
35. R. T. Bunch and A. Eastman, 7-Hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S-phase arrest in Chinese hamster ovary cells. Cell Growth Differ. 8, 779-788 (1997).
36. R. B. Painter and B. R. Young, Radiosensitivity in ataxia-telangiectasia: A new explanation. Proc. Natl. Acad. Sci. USA 77, 7315-7317 (1980).
37. M. F. Lavin and Y. Shiloh, The genetic defect in ataxia-telangiectasia. Annu. Rev. Immunol. 15, 177-202 (1996).